Journal of Shanghai Jiao Tong University (Medical Science) >

2023 , Vol. 43 >Issue 3: 320 - 332

DOI: https://doi.org/10.3969/j.issn.1674-8115.2023.03.008

Evidence-based medicine

Efficacy of radiotherapy in patients with rectal cancer undergoing chemotherapy and surgery: a retrospective study based on the SEER database

  • Anjun WANG ,
  • Ningning LIU
Expand
  • Shanghai Jiao Tong University School of Public Health, Shanghai 200025, China
LIU Ningning, E-mail: liuningning@shsmu.edu.cn.

Received date: 2022-08-18

  Accepted date: 2022-12-09

  Online published: 2023-03-28

Supported by

National Key R&D Program of China(2020YFA0907200);National Natural Science Foundation of China(31900129)

Fold

Abstract

Objective ·To evaluate the survival effects of neoadjuvant radiation therapy and adjuvant radiotherapy on the patients with rectal cancer treated with chemotherapy and surgery by using the Surveillance, Epidemiology and End Results (SEER) database of the United States. Methods ·The patients with pathologically confirmed rectal cancer and treated with chemotherapy and surgical resection from 2005 to 2015 in the SEER database were included; the patients with autopsy or death-only proof of rectal cancer, or without follow-up time and incomplete clinical data were excluded. All the patients were divided into neoadjuvant radiotherapy combined with surgery group (RT+S group), surgical treatment group (S group) and surgery combined with adjuvant radiotherapy group (S+RT group). The propensity score matching (PSM) was used to match the included subjects in each group at the 1∶1 ratio, and the restricted mean survival time (RMST) was used to estimate the mean survival of rectal cancer patients over 5 and 10 years. Cox proportional risk models were used to determine the effects of neoadjuvant and adjuvant radiotherapies on overall survival (OS) and tumor-specific survival (CSS) in the patients with rectal cancer, and the specific benefit groups of neoadjuvant and adjuvant radiotherapies were determined by stratified analysis of patients. Results ·From 2005 to 2015, 8 975 patients with rectal cancer who received chemotherapy and surgery were included, including 1 079 in the S group, 5 991 in the RT+S group, and 1 905 in the S+RT group. After PSM, the clinical base characteristics of the groups were balanced and comparable. The patients in the RT+S group had a significantly improved prognosis in 5 and 10 years compared with the S group (all P=0.000) after PSM, while the patients in the S+RT group had a significantly improved prognosis in 5 years only (both P<0.05) and no significant improvement in 10 years (both P>0.05). Multivariate Cox regression analysis showed that neoadjuvant radiotherapy was an independent protective factor for the patients′ OS and CSS (both P=0.000), while adjuvant radiotherapy was not (both P>0.05). Subgroup analysis showed that neoadjuvant radiotherapy had no significant protective effect on OS and CSS in the patients aged<50 years, with highly differentiated tumors, tumor size≤30 mm or TNM stage Ⅰ?Ⅲ (all P>0.05); whereas adjuvant radiotherapy had significant protective effects on OS and CSS in the patients with poorly differentiated/undifferentiated tumors, tumor size>50 mm or TNM stage Ⅳ (all P<0.05). Conclusion ·For the patients with rectal cancer treated with chemotherapy and surgery, neoadjuvant radiotherapy has a significant survival benefit, but it may not be applicable for the patients aged<50 years, with highly differentiated tumors, tumor size≤30 mm, or TNM stage Ⅰ?Ⅲ; whereas the patients with poorly differentiated/undifferentiated tumors, tumor size>50 mm, or TNM stage Ⅳ may benefit from adjuvant radiotherapy.

Key words： rectum cancer; neoadjuvant radiotherapy; adjuvant radiotherapy; SEER database; prognosis

Cite this article

Anjun WANG , Ningning LIU . Efficacy of radiotherapy in patients with rectal cancer undergoing chemotherapy and surgery: a retrospective study based on the SEER database[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023 , 43(3) : 320 -332 . DOI: 10.3969/j.issn.1674-8115.2023.03.008

References

1 SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2 ZHENG R S, ZHANG S W, ZENG H M, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1): 1-9.
3 BENSON A B, VENOOK A P, AL-HAWARY M M, et al. NCCN guidelines insights: colon cancer, version 2.2018[J]. J Natl Compr Canc Netw, 2018, 16(4): 359-369.
4 ROH M S, COLANGELO L H, O′CONNELL M J, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03[J]. J Clin Oncol, 2009, 27(31): 5124-5130.
5 Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials[J]. Lancet, 2001, 358(9290): 1291-1304.
6 MA B, GAO P, WANG H C, et al. What has preoperative radio(chemo)therapy brought to localized rectal cancer patients in terms of perioperative and long-term outcomes over the past decades? A systematic review and meta-analysis based on 41,121 patients[J]. Int J Cancer, 2017, 141(5): 1052-1065.
7 ZHONG W, XUE X J, DAI L Z, et al. Neoadjuvant treatments for resectable rectal cancer: a network meta-analysis[J]. Exp Ther Med, 2020, 19(4): 2604-2614.
8 MARTIN S T, HENEGHAN H M, WINTER D C. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer[J]. Br J Surg, 2012, 99(7): 918-928.
9 TRINQUART L, JACOT J, CONNER S C, et al. Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials[J]. J Clin Oncol, 2016, 34(15): 1813-1819.
10 WOLSKI A, GRAFFéO N, GIORGI R, et al. A permutation test based on the restricted mean survival time for comparison of net survival distributions in non-proportional excess hazard settings[J]. Stat Methods Med Res, 2020, 29(6): 1612-1623.
11 IRWIN J O. The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice[J]. J Hyg (Lond), 1949, 47(2): 188.
12 MAAS M, NELEMANS P J, VALENTINI V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data[J]. Lancet Oncol, 2010, 11(9): 835-844.
13 PARK I J, YOU Y N, AGARWAL A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer[J]. J Clin Oncol, 2012, 30(15): 1770-1776.
14 ARENAS PRAT M, SABATER S, BONET M, et al. EP-2303: should radiotherapy be avoided after neoadjuvant chemotherapy in complete response breast cancer?[J]. Radiother Oncol, 2018, 127: S1271.
15 LOGAN J K, HUBER K E, DIPETRILLO T A, et al. Patterns of care of radiation therapy in patients with stage Ⅳ rectal cancer: a Surveillance, Epidemiology, and End Results analysis of patients from 2004 to 2009[J]. Cancer, 2014, 120(5): 731-737.
16 BUJKO K, PARTYCKI M, PIETRZAK L. Neoadjuvant radiotherapy (5×5 Gy): immediate versus delayed surgery[J]. Recent Results Cancer Res, 2014, 203: 171-187.
17 BACH S P, GILBERT A, BROCK K, et al. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study[J]. Lancet Gastroenterol Hepatol, 2021, 6(2): 92-105.
18 HAYES I P, MILANZI E, GIBBS P, et al. Neoadjuvant chemoradiotherapy and tumor recurrence in patients with early T-stage cancer of the lower rectum[J]. Ann Surg Oncol, 2020, 27(5): 1570-1579.
19 MCLAUGHLIN C, KIM N K, BANDYOPADHYAY D, et al. Adjuvant radiation therapy for T4 non-rectal colon adenocarcinoma provides a cause-specific survival advantage: a SEER database analysis[J]. Radiother Oncol, 2019, 133: 50-53.
20 HUANG Y, GU X, GE K X, et al. The survival benefit of adjuvant radiotherapy for pathological T4N2M0 colon cancer in the Modern Chemotherapy Era: evidence from the SEER database 2004?2015[J]. Artif Cells Nanomed Biotechnol, 2020, 48(1): 834-840.
21 SIEGEL R L, JEMAL A, WARD E M. Increase in incidence of colorectal cancer among young men and women in the United States[J]. Cancer Epidemiol Biomarkers Prev, 2009, 18(6): 1695-1698.
22 WANG L, ZHONG X H, LIN H Q, et al. Identifying the long-term survival beneficiary of preoperative radiotherapy for rectal cancer in the TME era[J]. Sci Rep, 2022, 12(1): 4617.
23 KOLARICH A, GEORGE T J Jr, HUGHES S J, et al. Rectal cancer patients younger than 50 years lack a survival benefit from NCCN guideline-directed treatment for stage Ⅱ and Ⅲ disease[J]. Cancer, 2018, 124(17): 3510-3519.
24 STEINHAGEN E, SHIA, RIEDEL E, et al. Response to neoadjuvant therapy in patients with early age-of-onset rectal cancer[J]. Dis Colon Rectum, 2013, 56(1): 58-63.
25 ZHANG Y Y, YAN L L, WU Y, et al. Worse treatment response to neoadjuvant chemoradiotherapy in young patients with locally advanced rectal cancer[J]. BMC Cancer, 2020, 20(1): 854.
26 LEE S, MA C, ZHANG S, et al. Marital status, living arrangement, and cancer recurrence and survival in patients with stage Ⅲ colon cancer: findings from CALGB 89803 (Alliance)[J]. Oncologist, 2022, 27(6): e494-e505.
Options
Outlines

/

〈 〉